We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+8.56%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$14.8B
AUM Growth
+$1.79B
(+14%)
Cap. Flow
+$849M
Cap. Flow
% of AUM
5.76%
Top 10 Holdings %
Top 10 Hldgs %
16.89%
Holding
1,178
New
178
Increased
473
Reduced
324
Closed
161
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$128M |
| 2 |
Intel
INTC
|
+$88.4M |
| 3 |
Prudential Financial
PRU
|
+$72.7M |
| 4 |
Lam Research
LRCX
|
+$62.6M |
| 5 |
SBA Communications
SBAC
|
+$58M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Qualcomm
QCOM
|
+$98.3M |
| 2 |
Target
TGT
|
+$86.8M |
| 3 |
Occidental Petroleum
OXY
|
+$74.7M |
| 4 |
Synchrony
SYF
|
+$61.6M |
| 5 |
Intercontinental Exchange
ICE
|
+$57.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.69% |
| 2 | Healthcare | 13.54% |
| 3 | Financials | 13.08% |
| 4 | Consumer Discretionary | 12.97% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
601
Sprout Social
SPT
$509M
| $1.95M | 0.01% |
21,776
-2,976
| -12% | -$206K |
|
602
Resources Connection
RGP
$133M
| $1.93M | 0.01% |
134,607
+90,394
| +204% | +$1.31M |
|
|
DSPG
603
DELISTED
DSP Group Inc
DSPG
| $1.93M | 0.01% |
130,465
+6,046
| +5% | +$90.3K |
|
604
CDW
CDW
$17.6B
| $1.93M | 0.01% |
+11,048
| New | +$1.9M |
|
605
Travelzoo
TZOO
$104M
| $1.93M | 0.01% |
130,464
+46,024
| +55% | +$740K |
|
|
GRTX
606
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
| $1.92M | 0.01% |
195,220
+113,948
| +140% | +$926K |
|
607
Metropolitan Bank Holding Corp
MCB
$1.14B
| $1.92M | 0.01% |
31,831
+2,662
| +9% | +$162K |
|
608
Coherus Oncology
CHRS
$227M
| $1.92M | 0.01% |
138,551
-626,638
| -82% | -$8.87M |
|
609
Peapack-Gladstone Financial
PGC
$832M
| $1.91M | 0.01% |
61,549
+2,727
| +5% | +$88K |
|
610
Park-Ohio Holdings
PKOH
$549M
| $1.9M | 0.01% |
59,186
+2,715
| +5% | +$95.6K |
|
|
ZGNX
611
DELISTED
Zogenix, Inc.
ZGNX
| $1.9M | 0.01% |
109,851
+44,735
| +69% | +$823K |
|
612
Photronics
PLAB
$1.73B
| $1.89M | 0.01% |
142,949
+97,333
| +213% | +$1.27M |
|
613
Idacorp
IDA
$8.19B
| $1.88M | 0.01% |
19,309
-2,577
| -12% | -$258K |
|
614
Voyager Therapeutics
VYGR
$186M
| $1.88M | 0.01% |
455,663
-106,006
| -19% | -$480K |
|
615
Greenlight Captial
GLRE
$568M
| $1.87M | 0.01% |
204,517
+87,712
| +75% | +$804K |
|
616
Kforce
KFRC
$1.05B
| $1.85M | 0.01% |
29,427
-32,471
| -52% | -$1.92M |
|
617
Atara Biotherapeutics
ATRA
$70.2M
| $1.81M | 0.01% |
4,669
+1,918
| +70% | +$684K |
|
|
CNR
618
Core Natural Resources Inc
CNR
$4.14B
| $1.81M | 0.01% |
98,282
+2,368
| +2% | +$31.8K |
|
|
SPTN
619
DELISTED
SpartanNash
SPTN
| $1.81M | 0.01% |
93,577
-47,996
| -34% | -$957K |
|
620
Citizens Financial Group
CFG
$30B
| $1.79M | 0.01% |
39,109
+28,212
| +259% | +$1.33M |
|
|
MTEM
621
DELISTED
Molecular Templates, Inc.
MTEM
| $1.79M | 0.01% |
+15,296
| New | +$2M |
|
622
JPMorgan Chase
JPM
$944B
| $1.79M | 0.01% |
11,507
-4,187
| -27% | -$658K |
|
623
Kemper
KMPR
$1.75B
| $1.79M | 0.01% |
+24,182
| New | +$1.86M |
|
|
AGTC
624
DELISTED
Applied Genetic Technologies Corporation
AGTC
| $1.79M | 0.01% |
456,825
-12,799
| -3% | -$53.1K |
|
625
Orion Group Holdings
ORN
$496M
| $1.77M | 0.01% |
308,530
+98,839
| +47% | +$576K |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q2 2021 Portfolio in Review
As of Q2 2021, Jacobs Levy Equity Management held 1,178 positions worth $14.8B, up 14% from $13B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Jacobs Levy Equity Management deployed $849M of net new capital in Q2 2021, opening 178 new positions and adding to 473 existing holdings. Its largest new stake was Lam Research: 991,120 shares worth $64.5M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 22% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Qualcomm, an estimated $98.3M trimmed.
- Jacobs Levy Equity Management's largest Q2 2021 buy was Lam Research: 991,120 shares worth $64.5M.
- Jacobs Levy Equity Management added most to Vertex Pharmaceuticals in Q2 2021, an estimated $128M increase.
- Jacobs Levy Equity Management's biggest Q2 2021 reduction was Qualcomm, cutting an estimated $98.3M.
- Jacobs Levy Equity Management fully exited Occidental Petroleum in Q2 2021, selling an estimated $74.7M.
- Jacobs Levy Equity Management's ten largest holdings make up 17% of its $14.8B portfolio in Q2 2021.
- Jacobs Levy Equity Management opened 178 new positions and closed 161 in Q2 2021.
- Jacobs Levy Equity Management's portfolio value rose 14% quarter-over-quarter to $14.8B.
Based on Jacobs Levy Equity Management's 13F filing for Q2 2021, filed 16 Aug 2021.